乳腺癌超低分割放疗的临床结局与单中心经验
本研究基于COVID-19疫情及FAST-Forward研究发表背景,快速在早期乳腺癌患者中实施超低分割放疗(U-HFRT,26 Gy/5次),并与中等低分割放疗(M-HFRT,40.05 Gy/15次)比较皮肤毒性。共评估320例0-II期乳腺癌患者,U-HFRT组133例(41.6%),M-HFRT组187例(58.4%)。多因素分析显示M-HFRT组放疗期间1级以上皮肤毒性显著更多(OR=32.3,P<.001),而放疗后1-90天M-HFRT组1级以上毒性更少(OR=0.36,P=.014)。
要点
- U-HFRT(26 Gy/5次)用于0-II期乳腺癌术后全乳放疗,放疗期间急性皮肤毒性低于M-HFRT。
- 放疗后1-90天M-HFRT组1级以上皮肤毒性反而更少(OR=0.36,P=.014)。
- 放疗后90天以上皮肤毒性总体发生率低,但需更长期随访确认局部控制与晚期正常组织毒性。
核心结论
- U-HFRT(26 Gy/5次)在0-II期乳腺癌术后全乳放疗中急性皮肤毒性低于M-HFRT(40.05 Gy/15次),可作为特定患者的标准方案。
研究设计与样本
- 单中心回顾性研究,连续纳入2020年5月至2021年3月接受辅助全乳放疗的0-II期乳腺癌患者320例,分为U-HFRT组133例(41.6%)和M-HFRT组187例(58.4%)。
主要发现
- U-HFRT组诊断中位年龄65.4岁(范围57-73),71%为激素受体阳性浸润性疾病,18%为导管原位癌,33%接受瘤床加量。
- U-HFRT更多用于年龄较大、激素受体阳性且未接受瘤床加量的患者(P<.001)。
- 多因素分析显示M-HFRT组放疗期间1级以上皮肤毒性显著更多(OR=32.3,P<.001)。
- 调整瘤床加量、年龄和化疗后,放疗后1-90天M-HFRT组1级以上皮肤毒性更少(OR=0.36,P=.014)。
- 放疗后90天以上皮肤毒性总体发生率低。
关键数值与推荐
- U-HFRT方案为26 Gy/5次,M-HFRT方案为40.05 Gy/15次,均给予全乳放疗。
- 皮肤毒性采用RTOG放射损伤分级评估,时间点为基线/放疗期间、放疗后1-90天及放疗后90天以上。
临床怎么用
- 对年龄较大、激素受体阳性且无需瘤床加量的0-II期乳腺癌患者,可考虑选择U-HFRT(26 Gy/5次)以降低放疗期间急性皮肤毒性。
- 需注意放疗后1-90天M-HFRT组皮肤毒性反而更少,临床随访中应关注不同分割方案毒性时间分布的差异。
- 长期局部控制和晚期正常组织毒性需更长时间随访确认。
局限性
- 单中心回顾性研究,非随机分组,存在选择偏倚。
- 随访时间较短,无法评估长期局部控制和晚期正常组织毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prompted by COVID-19 and publication of the FAST-Forward study, our institution rapidly implemented ultrahypofractionated radiation therapy (U-HFRT) for patients with early-stage breast cancer. Our objective was to evaluate our early experience and toxicity outcomes for U-HFRT. METHODS AND MATERIALS: Patients with consecutive stage 0-II breast cancer treated with adjuvant whole breast radiation therapy (RT) were evaluated. Patient demographics and treatment characteristics were extracted and categorized into 2 cohorts: U-HFRT, 26 Gy/5 fractions (F) and M (moderate)-HFRT, 40.05 Gy/15F. Physician-assessed skin toxicity was evaluated using the Radiation Therapy Oncology Group radiation morbidity scale at baseline/during RT, 1 to 90 days post-RT and >90 days post-RT. Descriptive statistics summarized patient demographics and treatment characteristics and were stratified based on dose fractionation. A multivariable logistic model evaluated associations between toxicity and fractionation. RESULTS: Between May 2020 and March 2021, 320 patients were evaluated: 133 (41.6%) received U-HFRT and 187 (58.4%) received M-HFRT. For the U-HFRT cohort, median age at diagnosis was 65.4 years (range, 57-73), 71% had hormone receptor-positive invasive disease, and 18% had ductal carcinoma in-situ. All patients received whole breast RT, and 33% received a boost. U-HFRT was used more in patients who were older, hormone receptor-positive, and did not receive a boost (P < .001). On multivariable analysis, M-HFRT patients experienced significantly more grade 1+skin toxicity during RT (odds ratio = 32.3, P < .001), while 1 to 90 days post-RT, M-HFRT patients experienced less grade 1+ toxicity (odds ratio = 0.36, P < .014) after adjusting for boost, age, and chemotherapy. Rates of skin toxicity >90 days post-RT were low overall. CONCLUSIONS: This study reports real-world clinical outcomes of patients with stage 0-II breast cancer treated with U-HFRT. We observed low rates of acute skin toxicity compared to M-HFRT, confirming its acceptability as a standard regimen for select patients. Longer term follow-up would be necessary to confirm clinical outcomes in terms of both local control and late normal tissue toxicity.
引用
- Othman H, Barry A, Fyles A, et al. Clinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Adv Radiat Oncol. 2025. PMID: 41541755. doi:10.1016/j.adro.2025.101948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。